AlphAIAlphAI — Financial news for AI agents
StockNASDAQ · US · USDHealthcare · Biotechnology

$CNSP

CNS Pharmaceuticals, Inc.

Price · $CNSPvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $CNSP in the last 7 days.

Insider · 30dAll trades →

No SEC Form 4 filings for $CNSP in the last 30 days.

See all $CNSP insider activity →
Top stories · $CNSPMore →
AUG 18·rttnews.comMed

Biotech Stocks Rally: AMLX, RCEL, CNSP Gain On Key Clinical And Corporate News

Amylyx Pharmaceuticals (AMLX) rose 55.71% after positive Phase 3 LUCIDITY trial results for Avexitide. AVITA Medical (RCEL) gained 21.90% on cost-effective PermeaDerm-I study data. CNS Pharmaceuticals (CNSP) increased 12.04% following a strategic financing and pipeline pivot. Orchestra BioMed (OBIO) advanced 15.04% with strategic capital and hypertension program progress. NeOnc Technologies (NTHI) climbed 13.80% on encouraging Phase 2a NEO100 data.

AUG 12·news.alphastreet.com

CNS Pharmaceuticals Releases Q2 2026 Financial Results

CNS Pharmaceuticals (CNSP) reported Q2 2026 results with a basic and diluted loss of $0.37 per share, wider than the expected $0.24, and a net loss of $2.6M. The company said the per-share loss improved 94.2% year over year versus Q2 2025. Analysts’ consensus cited 4 buys, 1 hold, 0 sells.

CNSP sentiment & insider activity

Recent CNSP coverage spans financial news, market movers and insider activity.

What's driving CNSP

  • Financing plus a stated pivot to in-license or acquire assets can re-rate the risk profile, but execution risk remains high.

    rttnews.com · Aug 18, 2026

  • A small, non-10b5-1 insider open-market purchase provides mild sentiment support but is unlikely to change fundamentals.

    SEC EDGAR · Aug 18, 2026

  • The quarter shows near-term earnings pressure but also a large year-over-year loss improvement, which can affect sentiment and near-term positioning.

    news.alphastreet.com · Aug 12, 2026

  • The amended 10-K/A for CNS Pharmaceuticals updates executive compensation, ownership structure, and other corporate governance details. No immediate material financial impact is evident, but the updates may influence investor perception.

    Stock Titan · May 1, 2026

  • CNS Pharmaceuticals is shifting focus from glioblastoma to neurology and oncology pipelines amid financial distress and a going concern risk. The company's recent trial failure and limited cash runway suggest increased volatility and downside risk, but potential upside if new pipeline strategies succeed.

    Stock Titan · Apr 1, 2026

AlphAI scores every news story that mentions CNSP with an AI model for sentiment and relevance, and aggregates insider trades from CNS Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CNSP

Score
AUG 18$AMLXMedrttnews.com

Biotech Stocks Rally: AMLX, RCEL, CNSP Gain On Key Clinical And Corporate News

Amylyx Pharmaceuticals (AMLX) rose 55.71% after positive Phase 3 LUCIDITY trial results for Avexitide. AVITA Medical (RCEL) gained 21.90% on cost-effective PermeaDerm-I study data. CNS Pharmaceuticals (CNSP) increased 12.04% following a strategic financing and pipeline pivot. Orchestra BioMed (OBIO) advanced 15.04% with strategic capital and hypertension program progress. NeOnc Technologies (NTHI) climbed 13.80% on encouraging Phase 2a NEO100 data.

4 min read
APR 1$CNSPLowStock Titan

CNS Pharmaceuticals (NASDAQ: CNSP) pivots to neurology and oncology amid going concern risk

CNS Pharmaceuticals (NASDAQ: CNSP) is undergoing a strategic pivot, shifting its focus from solely glioblastoma to building an in-licensed pipeline in neurology and oncology. This change follows the Phase 2 trial failure of its legacy asset Berubicin to demonstrate superiority over lomustine in overall survival. The company faces a going concern risk, with cash flow projections indicating it can fund operations only into the third quarter of 2026, necessitating additional capital.

4 min read
APR 1$CNSPMedTradingView

CNS Pharmaceuticals 10-K: Net loss $15.85M, Loss per share $35.75

CNS Pharmaceuticals reported a net loss of $15.85 million for the year, primarily due to increased research and development spending for clinical programs. The company's operating loss totaled $15.99 million, with a loss per basic share of $35.75 based on 443,369 weighted average shares outstanding. They also raised equity in 2025 to fund operations and trials through mid-2026.

2 min read
MAR 2$CNSPMedTipRanks

CNS Pharmaceuticals appoints Lynne Kelley as CMO

CNS Pharmaceuticals (CNSP) has appointed Lynne Kelley, MD, FACS, as its new Chief Medical Officer (CMO). Dr. Kelley previously served as CMO at several biotechnology and medical device companies, including TISSIUM, Servier Pharmaceuticals, X4 Pharmaceuticals, and Senseonics. This appointment follows recent restructuring in the company's financial leadership.

2 min read

Related tickers

More in Biotechnology